Pharmaceuticals

3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration

SHENYANG, China and BEDFORD Mass., Nov. 17, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (HKEX:1530) and Verseau Therapeutics, Inc.  ("Verseau") today announced the selection of VTX-0811, a monoclonal antibody targeting PSGL-1, as the first lice...

2019-11-18 08:30 2387

Viva Biotech Partnership Summit Successfully Launched in Shanghai

SHANGHAI, Nov. 15, 2019 /PRNewswire/ -- 2019 Viva Biotech Partnership Summit (the "Summit") was successfully launched on8 November 2019 in Pudong, Shanghai, themed "Innovation Partnership Growth". Founders from over 30 global innovative and biopharmaceutical companies incubated/ invested by Viva ...

2019-11-15 14:16 598

I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced that Natio...

2019-11-14 23:45 482

Samsung Biologics Enhances Its Trusted Service as the First and Only ISO27001 Certified CDMO

INCHEON, South Korea, Nov. 14, 2019 /PRNewswire/ -- Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security management. Samsung Biologics is the first CDMO company to be ISO 27001 certified globally. A ceremony...

2019-11-14 20:00 363

China Biologic Reports Financial Results for the Third Quarter of 2019

BEIJING, Nov. 13, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the third quarter of 2019. Third Quarter...

2019-11-14 05:43 5510

Akesobio Presents Phase 1 Clinical Data from First-in-class Bispecific Drug Candidate AK104 (PD1/CTLA4) As Oral Presentation, at 2019 SITC Annual Meeting

NATIONAL HARBOR, Md., Nov. 11, 2019 /PRNewswire/ -- Akeso Biopharma ("Akeso") presented results of phase 1 study of its first-in-class bispecific drug candidate  AK104, in patients with advanced solid tumors in 2019 Society for Immunotherapy of Cancer ("SITC"). AK104 is a novel, tetrameric bispec...

2019-11-11 17:35 393

Enzene Opens its First Continuous Biologics Manufacturing Facility With a Promise to Disrupt the mAb Manufacturing Cost

PUNE, India, Nov. 7, 2019 /PRNewswire/ -- Enzene Biosciences today formally opened its first fully connected continuous Biologics manufacturing facility in Pune, India. This first-of-its-kind facility was built in half the time as compared to the conventional biologics manufacturing plants. The s...

2019-11-07 20:24 448

TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma

NANJING, China, Nov. 7, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, announced today that company received Orphan Drug Designation from US Food and Drug Administration (FDA) for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma. Dr. Frank Wu, Founde...

2019-11-07 20:08 369

Polynoma Presenting Interim Phase III Data for Its Investigational Melanoma Vaccine, Seviprotimut-L, at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients -- SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary ofHon...

2019-11-06 20:00 5063

Samsung Biologics and Ichnos Sciences Announce Agreement for Manufacture of ISB 830

INCHEON, South Korea, Nov. 4, 2019 /PRNewswire/ -- Samsung Biologics announced the signing of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis....

2019-11-05 08:22 404

Luye Pharma's LY03004 Manufacturing Facility Successfully Passes U.S. FDA Pre-approval Inspection with Zero Observation

SHANGHAI, Nov. 4, 2019 /PRNewswire/ -- LY03004, Luye Pharma's innovative, independently developed Extended-Release Microspheres for Injection has taken another step closer to going on the U.S. market. The company has announced that it has received the Establishment Inspection Report from the U.S....

2019-11-05 00:39 435

China Biologic Products to Report Third Quarter 2019 Financial Results

BEIJING, Nov. 4, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its third quarter 2019 financial results o...

2019-11-04 21:30 6218

Mallinckrodt and Terumo BCT Announce UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for the Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults

SYDNEY, Nov. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that UVADEX®  (methoxsalen) has received regulatory approval inAustralia by th...

2019-11-01 04:35 5639

GC Pharma Reports Q3 2019 Results

YONGIN, South Korea, Oct. 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedSeptember 30, 2019. Key Figures Q3 2019(1) Growth(1) Total revenues K...

2019-10-30 21:00 5271

Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis

- ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ...

2019-10-28 20:30 2614

HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH)

SINGAPORE, Oct. 26, 2019 /PRNewswire/ -- HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve quantifiable and reproducible...

2019-10-26 19:00 611

Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences

SAN FRANCISCO and SUZHOU, China, Oct. 26, 2019 /PRNewswire/ -- Adagene, Inc., a clinical stage biotech company with innovative antibody discovery and engineering technologies, announced that it is presenting its lead program at international conferences.  During the Festival of Biologics confere...

2019-10-26 18:01 742

World first clinical trial commenced in alcohol use disorder

MELBOURNE, Australia, Oct. 24, 2019 /PRNewswire/ -- A medication currently used to treat insomnia may also be effective in preventing alcohol intake and relapse in alcohol use disorder, according to researchers at the Florey Institute of Neuroscience and Mental Health. A world-first clinical stu...

2019-10-24 12:01 348

GN Corporation and Edogawa Evolutionary Laboratory of Science Cosponsor International Academic Conference, NCRM NICHE 2019, on October 15, 2019

KOFU, Japan and TOKYO, Oct. 21, 2019 /PRNewswire/ -- GN Corporation Co., Ltd., a Japanese firm involved in research and development of technology in regenerative medicine, and Edogawa Evolutionary Laboratory of Science(EELS), a unit ofTokyo's Edogawa Hospital, cosponsored NCRM NICHE 2019 (www.ncr...

2019-10-21 14:00 405

Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas

AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical S...

2019-10-18 20:30 9677
123456 ... 42